Cannabis is widely recognized for its medical potential, but who is truly investing in the pharmaceutical approach? While much of the industry focuses on adult use, companies prioritizing R&D, clinical trials, and advanced drug delivery systems are quietly shaping the future of cannabis as medicine. This panel explores the high-investment, high-reward path to true pharmaceutical integration—and why it matters now more than ever.